摘要
成纤维细胞生长因子FGF 19的扩增及其受体FGFR 4的过度表达与下游跨膜酶β-klotho h的过度激活已经发现在肿瘤的发展和进展中起着关键的作用。异常的fgf 19-fgfr 4信号被认为与特定的致瘤事件有关，包括癌细胞外露。诱导，凋亡抗性和转移，激活无数下游信号级联。作为一个有吸引力的目标，为扰乱fgf 19-fgfr 4轴心而实施的几项战略如下：EN是近年来发展起来的，FGF19-FGFR 4结合抑制剂因其在治疗FGF19-FGFR 4中的临床应用而受到广泛的评价。根据已经确定的工作，这是VIEW旨在详细说明fgf 19-fgfr 4信号通路是如何在癌症进展中起重要作用的，以及为什么中断fgf 19与fgfr 4之间的通讯是一种有希望的治疗策略f。或者破坏癌症的进展。
关键词: FGF 19，FGFR 4，β-Klotho，癌症，靶标，药物开发。
图形摘要
[1]
Degirolamo, C.; Sabbà, C.; Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov., 2016, 15(1), 51-69.
[2]
Nishimura, T. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta, 1999, 1444(1), 148-151.
[3]
Itoh, N.; Ornitz, D.M. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn., 2008, 237(1), 18-27.
[4]
Mohammadi, M.; Olsen, S.K.; Ibrahimi, O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev., 2005, 16(2), 107-137.
[5]
Beenken, A.; Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 2009, 8(3), 235-253.
[6]
Miura, S.; Mitsuhashi, N.; Shimizu, H.; Kimura, F.; Yoshidome, H.; Otsuka, M.; Kato, A.; Shida, T.; Okamura, D.; Miyazaki, M. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer, 2012, 12(1), 56.
[7]
Desnoyers, L.R.; Pai, R.; Ferrando, R.E.; Hötzel, K.; Le, T.; Ross, J.; Carano, R.; D’souza, A.; Qing, J.; Mohtashemi, I.; Ashkenazi, A. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene, 2008, 27(1), 85-97.
[8]
Spinola, M.; Leoni, V.; Pignatiello, C.; Conti, B.; Ravagnani, F.; Pastorino, U.; Dragani, T.A. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J. Clin. Oncol., 2005, 23(29), 7307-7311.
[9]
Feng, S.; Dakhova, O.; Creighton, C.J.; Ittmann, M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res., 2013, 73(8), 2551-2562.
[10]
Buhmeida, A.; Dallol, A.; Merdad, A.; Al-Maghrabi, J.; Gari, M.A.; Abu-Elmagd, M.M.; Chaudhary, A.G.; Abuzenadah, A.M.; Nedjadi, T.; Ermiah, E.; Al-Thubaity, F. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour Biol., 2014, 35(3), 2817-2824.
[11]
Tiong, K.H.; Tan, B.S.; Choo, H.L.; Chung, F.F.L.; Hii, L.W.; Tan, S.H.; Khor, N.T.W.; Wong, S.F.; See, S.J.; Tan, Y.F.; Rosli, R. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget, 2016, 7(36), 57633.
[12]
Zhang, X.; Wang, Z.; Tian, L.; Xie, J.; Zou, G.; Jiang, F. increased expression of fgf19 contributes to tumor progression and cell motility of human thyroid cancer. Otolaryngol. Head Neck Surg., 2016, 154(1), 52-58.
[13]
Sawey, E.T.; Chanrion, M.; Cai, C.; Wu, G.; Zhang, J.; Zender, L.; Zhao, A.; Busuttil, R.W.; Yee, H.; Stein, L.; French, D.M. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell, 2011, 19(3), 347-358.
[14]
Zhao, H.; Lv, F.; Liang, G.; Huang, X.; Wu, G.; Zhang, W.; Yu, L.; Shi, L.; Teng, Y. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3beta/beta- catenin signaling cascade via FGFR4 activation. Oncotarget, 2016, 7(12), 13575-13586.
[15]
Nicholes, K.; Guillet, S.; Tomlinson, E.; Hillan, K.; Wright, B.; Frantz, G.D.; Pham, T.A.; Dillard-Telm, L.; Tsai, S.P.; Stephan, J.P.; Stinson, J. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol., 2002, 160(6), 2295-2307.
[16]
Uriarte, I.; Latasa, M.U.; Carotti, S.; Fernandez‐Barrena, M.G.; Garcia‐Irigoyen, O.; Elizalde, M.; Urtasun, R.; Vespasiani‐Gentilucci, U.; Morini, S.; de Mingo, A.; Mari, M. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int. J. Cancer, 2015, 136(10), 2469-2475.
[17]
Wang, S.; Zhao, D.; Tian, R.; Shi, H.; Chen, X.; Liu, W.; Wei, L. FGF19 Contributes to Tumor Progression in Gastric Cancer by Promoting Migration and Invasion. Oncol. Res. Featuring Preclin. Clin. Cancer Ther, 2016, 23(4), 197-203.
[18]
Hu, L.; Cong, L. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncol. Rep., 2015, 34(5), 2683-2691.
[19]
Cui, Y.; Liu, J.; Liu, Y.; Liu, J.H. Upregulation of FGF19 in lung adenocarcinoma and predicts poor prognosis. Int. J. Clin. Exp. Pathol., 2016, 9(7), 7338-7344.
[20]
Valastyan, S.; Weinberg, R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell, 2011, 147(2), 275-292.
[21]
Tan, Q.; Li, F.; Wang, G.; Xia, W.; Li, Z.; Niu, X.; Ji, W.; Yuan, H.; Xu, Q.; Luo, Q.; Zhang, J. Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. Oncotarget, 2016, 7(14), 18394.
[22]
Teishima, J.; Yano, S.; Shoji, K.; Hayashi, T.; Goto, K.; Kitano, H.; Oka, K.; Nagamatsu, H.; Matsubara, A. Accumulation of FGF9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression. Anticancer Res., 2014, 34(2), 695-700.
[23]
Dienstmann, R.; Rodon, J.; Prat, A.; Perez-Garcia, J.; Adamo, B.; Felip, E.; Cortes, J.; Iafrate, A.J.; Nuciforo, P.; Tabernero, J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol., 2014, 25(3), 552-563.
[24]
Li, S.Q.; Cheuk, A.T.; Shern, J.F.; Song, Y.K.; Hurd, L.; Liao, H.; Wei, J.S.; Khan, J. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One, 2013, 8(10), e76551.
[25]
Gao, L.; Wang, X.; Tang, Y.; Huang, S.; Hu, C.A.A.; Teng, Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J. Exp. Clin. Cancer Res., 2017, 36(1), 8.
[26]
Shimizu, M.; Li, J.; Maruyama, R.; Inoue, J.; Sato, R. FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress. Biochem. J., 2013, 450(1), 221-229.
[27]
Kurosu, H.; Choi, M.; Ogawa, Y.; Dickson, A.S.; Goetz, R.; Eliseenkova, A.V.; Mohammadi, M.; Rosenblatt, K.P.; Kliewer, S.A.; Kuro-o, M. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem., 2007, 282(37), 26687-26695.
[29]
Owen, B.M.; Mangelsdorf, D.J.; Kliewer, S.A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab., 2015, 26(1), 22-29.
[30]
Wu, X.; Ge, H.; Gupte, J.; Weiszmann, J.; Shimamoto, G.; Stevens, J.; Hawkins, N.; Lemon, B.; Shen, W.; Xu, J.; Veniant, M.M. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem., 2007, 282(40), 29069-29072.
[31]
Poh, W.; Wong, W.; Ong, H.; Aung, M.O.; Lim, S.G.; Chua, B.T.; Ho, H.K. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol. Cancer, 2012, 11(1), 14.
[32]
Feng, S.; Dakhova, O.; Creighton, C.J.; Ittmann, M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res., 2013, 73(8), 2551-2562.
[33]
Xu, Y.F.; Yang, X.Q.; Lu, X.F.; Guo, S.; Liu, Y.; Iqbal, M.; Ning, S.L.; Yang, H.; Suo, N.; Chen, Y.X. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem. Biophys. Res. Commun., 2014, 446(1), 54-60.
[34]
Peláez-García, A.; Barderas, R.; Torres, S.; Hernández-Varas, P.; Teixidó, J.; Bonilla, F.; de Herreros, A.G.; Casal, J.I. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One, 2013, 8(5), e63695.
[35]
Zhao, Y.; Meng, C.; Wang, Y.; Huang, H.; Liu, W.; Zhang, J.F.; Zhao, H.; Feng, B.; Leung, P.S.; Xia, Y. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes. Am. J. Physiol. Endocrinol. Metab., 2016, 310(4), E289-E300.
[36]
Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D. Identification of a nuclear receptor for bile acids. Science, 1999, 284(5418), 1362-1365.
[37]
Miyata, M.; Hata, T.; Yamakawa, H.; Kagawa, T.; Yoshinari, K.; Yamazoe, Y. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J. Steroid Biochem. Mol. Biol., 2012, 132(1), 41-47.
[38]
Wang, H.; Venkatesh, M.; Li, H.; Goetz, R.; Mukherjee, S.; Biswas, A.; Zhu, L.; Kaubisch, A.; Wang, L.; Pullman, J.; Whitney, K. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J. Clin. Invest., 2011, 121(8), 3220-3232.
[39]
Schmidt, D.R.; Holmstrom, S.R.; Tacer, K.F.; Bookout, A.L.; Kliewer, S.A.; Mangelsdorf, D.J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem., 2010, 285(19), 14486-14494.
[40]
Wistuba, W.; Gnewuch, C.; Liebisch, G.; Schmitz, G.; Langmann, T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol., 2007, 13(31), 4230.
[41]
Cheng, J.; Fang, Z.Z.; Nagaoka, K.; Okamoto, M.; Qu, A.; Tanaka, N.; Kimura, S.; Gonzalez, F.J. Activation of Intestinal Human Pregnane X Receptor Protects against Azoxymethane/Dextran Sulfate Sodium–Induced Colon Cancer. J. Pharmacol. Exp. Ther., 2014, 351(3), 559-567.
[42]
Pai, R.; French, D.; Ma, N.; Hotzel, K.; Plise, E.; Salphati, L.; Setchell, K.D.; Ware, J.; Lauriault, V.; Schutt, L.; Hartley, D. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci., 2012, 126(2), 446-456.
[43]
Ornitz, D.M.; Itoh, N. The fibroblast growth factor signaling pathway. Dev. Biol., 2015, 4(3), 215-266.
[44]
Fon Tacer, K.; Bookout, A.L.; Ding, X.; Kurosu, H.; John, G.B.; Wang, L.; Goetz, R.; Mohammadi, M.; Kuro-o, M.; Mangelsdorf, D.J.; Kliewer, S.A. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol., 2010, 24(10), 2050-2064.
[45]
Mencke, R.; Olauson, H.; Hillebrands, J-L. Effects of Klotho on fibrosis and cancer: A renal focus on mechanisms and therapeutic strategies. Adv. Drug Deliv. Rev., 2017, 121, 85-100.
[46]
Hu, M.C.; Shi, M.; Cho, H.J.; Adams-Huet, B.; Paek, J.; Hill, K.; Shelton, J.; Amaral, A.P.; Faul, C.; Taniguchi, M.; Wolf, M. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J. Am. Soc. Nephrol., 2015, 26(6), 1290-1302.
[47]
Chen, T.H.; Kuro-o, M.; Chen, C.H.; Sue, Y.M.; Chen, Y.C.; Wu, H.H.; Cheng, C.Y. The secreted Klotho protein restores hosphate retention and suppresses accelerated aging in Klotho mutant mice. Eur. J. Pharmacol., 2013, 698(1), 67-73.
[48]
Goetz, R. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol. Cell. Biol., 2012, 32(10), 1944-1954.
[49]
Turner, N.; Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 2010, 10(2), 116-129.
[50]
Heinzle, C.; Erdem, Z.; Paur, J.; Grasl-Kraupp, B.; Holzmann, K.; Grusch, M.; Berger, W.; Marian, B. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr. Pharm. Des., 2014, 20(17), 2881-2898.
[51]
Cavallaro, U.; Niedermeyer, J.; Fuxa, M.; Christofori, G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol., 2001, 3(7), 650.
[52]
Turkington, R.C.; Longley, D.B.; Allen, W.L.; Stevenson, L.; McLaughlin, K.; Dunne, P.D.; Blayney, J.K.; Salto-Tellez, M.; Van Schaeybroeck, S.; Johnston, P.G. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis., 2014, 5(2), e1046.
[53]
Zaid, T.M.; Yeung, T.L.; Thompson, M.S.; Leung, C.S.; Harding, T.; Schmandt, R.S.; Kwan, S.Y.; Rodriguez-Aguay, C.; Lopez-Berestein, G.; Sood, A.K.; Wong, K.K. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin. Cancer Res., 2013, 19(4), 809-820.
[54]
Shi, S.; Li, X.; You, B.; Shan, Y.; Cao, X.; You, Y. High expression of FGFR4 enhances tumor growth and metastasis in nasopharyngeal carcinoma. J. Cancer, 2015, 6(12), 1245.
[55]
Shah, R.N.; Ibbitt, J.C.; Alitalo, K.; Hurst, H.C. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α. Oncogene, 2002, 21(54), 8251.
[56]
French, D.M.; Lin, B.C.; Wang, M.; Adams, C.; Shek, T.; Hötzel, K.; Bolon, B.; Ferrando, R.; Blackmore, C.; Schroeder, K.; Rodriguez, L.A. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One, 2012, 7(5), e36713.
[57]
Wolf, J.; LoRusso, P.M.; Camidge, R.D.; Perez, J.M.; Tabernero, J.; Hidalgo, M.; Schuler, M.; Tian, G.G.; Soria, J.C.; Delord, J.P.; Campone, M. Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res., 2012, 72(8)(Suppl.), LB-122-LB-122.
[58]
Gavine, P.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M.J.; Brooks, A.N. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res., 2012, 72(8), 2045-2056.
[59]
Tan, L.; Wang, J.; Tanizaki, J.; Huang, Z.; Aref, A.R.; Rusan, M.; Zhu, S.J.; Zhang, Y.; Ercan, D.; Liao, R.G.; Capelletti, M. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl. Acad. Sci., 2014, 111(45), E4869-E4877.
[60]
Tabernero, J.; Bahleda, R.; Dienstmann, R.; Infante, J.R.; Mita, A.; Italiano, A.; Calvo, E.; Moreno, V.; Adamo, B.; Gazzah, A.; Zhong, B.; Phase, I. Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J. Clin. Oncol., 2015, 33(30), 3401-3408.
[61]
Tie, J.; Bang, Y.J.; Park, Y.S.; Kang, Y.K.; Monteith, D.; Hartsock, K.; Thornton, D.E.; Michael, M. Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cancer. Cancer Res., 2014, 74(19)(Suppl.), CT215-CT215.
[62]
Repana, D.; Ross, P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases, 2015, 3(4), 294-305.
[63]
Hagel, M.; Miduturu, C.; Sheets, M.; Rubin, N.; Weng, W.; Stransky, N.; Bifulco, N.; Kim, J.L.; Hodous, B.; Brooijmans, N.; Shutes, A. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov., 2015, 5(4), 424-437.
Call for Papers in Thematic Issues
31 December, 2025
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
31 December, 2025
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
31 December, 2025
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
31 December, 2025
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Delivery
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Article Metrics
97
8